Engineering of cell microenvironment-responsive polypeptide nanovehicle co-encapsulating a synergistic combination of small molecules for effective chemotherapy in solid tumors

Acta Biomaterialia

Volumn 48, Issue , 2017, Pages 131-143

  Ramasamy, Thiruganesh ^a   Ruttala, Hima Bindu ^a   Chitrapriya, Nataraj ^a   Poudal, Bijay Kumar ^a   Choi, Ju Yeon ^a   Kim, Ssang Tae ^a   Youn, Yu Seok ^b   Ku, Sae Kwang ^c   Choi, Han Gon ^d   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Daegu Haany University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Combination; Doxorubicin; Nanovehicle; Polypeptide; Quercetin

Indexed keywords

AMINO ACIDS; CELL DEATH; CELL ENGINEERING; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DISEASES; ENZYME ACTIVITY; ENZYME INHIBITION; ETHYLENE GLYCOL; PHENOLS; POLYETHYLENE GLYCOLS; POLYOLS; SHRINKAGE; TARGETED DRUG DELIVERY; TUMORS;

BIOACTIVES; COMBINATION; CYTOTOXIC; DOXORUBICIN; DRUG RELEASE; FACILE METHOD; NANOVEHICLES; POLY(L-HISTIDINE); POLY-L-HISTIDINE; QUERCETIN;

FLAVONOIDS;

CASPASE 3; CD31 ANTIGEN; DOXORUBICIN; DRUG VEHICLE; GLUTATHIONE; GLUTATHIONE DISULFIDE; KI 67 ANTIGEN; POLY(PHENYLALANINE) B POLY( L HISTIDINE ) B POLY(ETHYLENE GLYCOL) POLYPEPTIDE; POLYPEPTIDE; QUERCETIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; MOLECULAR LIBRARY; NANOPARTICLE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; MOUSE; NANOFABRICATION; NONHUMAN; OXIDATIVE STRESS; PH; PRIORITY JOURNAL; SOLID TUMOR; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL MOTION; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; ENDOCYTOSIS; FLOW CYTOMETRY; HYDRODYNAMICS; IMMUNOHISTOCHEMISTRY; MOLECULAR LIBRARY; NEOPLASMS; PARTICLE SIZE; PATHOLOGY; PHARMACOLOGY; PROCEDURES; THERAPEUTIC USE; TISSUE ENGINEERING; TREATMENT OUTCOME; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELLULAR MICROENVIRONMENT; DOXORUBICIN; DRUG CARRIERS; DRUG SYNERGISM; ENDOCYTOSIS; FLOW CYTOMETRY; HYDRODYNAMICS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; MICE; NANOPARTICLES; NEOPLASMS; OXIDATIVE STRESS; PARTICLE SIZE; PEPTIDES; QUERCETIN; SMALL MOLECULE LIBRARIES; TISSUE ENGINEERING; TREATMENT OUTCOME;

EID: 85005917627     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2016.10.034     Document Type: Article

References (52)

1. [1] Woodcock, J., Griffin, J.P., Behrman, R.E., Development of novel combination therapies. N. Engl. J. Med. 364 (2011), 985–987.
2. [2] Jabr-Milane, L.S., van Vlerken, L.E., Yadav, S., Amiji, M.M., Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 34 (2008), 592–602.
3. [3] Duan, X., Xiao, J., Yin, Q., Zhang, Z., Yu, H., Mao, S., Li, Y., Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 7 (2013), 5858–5869.
4. [4] Ma, L., Kohli, M., Smith, A., Nanoparticles for combination drug therapy. ACS Nano 7 (2013), 9518–9525.
5. [5] Gianni, L., Valagussa, P., Anthracyclines and early breast cancer: the end of an era?. J. Clin. Oncol. 27 (2009), 1155–1157.
6. [6] Gottesman, M.M., Fojo, T., Bates, S.E., Multidrug resistance in cancer: role of ATP–dependent transporters. Nat. Rev. Cancer 2 (2002), 48–58.
7. [7] Andreetta, C., Minisini, A.M., Miscoria, M., Puglisi, F., First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit. Rev. Oncol./Hematol. 76 (2010), 99–111.
8. [8] Ramasamy, T., Kim, J.H., Choi, H.G., Yong, C.S., Kim, J.O., Novel dual drug-loaded block ionomer complex micelles for enhancing the efficacy of chemotherapy treatments. J. Biomed. Nanotechnol. 10 (2014), 1304–1312.
9. [9] Ramasamy, T., Kim, J.H., Choi, J.Y., Tran, T.H., Choi, H.G., Yong, C.S., Kim, J.O., PH sensitive polyelectrolyte complex micelles for highly effective combination chemotherapy. J. Mater. Chem. B 2 (2014), 6324–6333.
10. [10] Lipshultz, S., Lipsitz, S., Mone, S., Silber, J., Jakacki, R., Larsen, R., Goldwein, J., Barber, G., Barber, G., Silber, J., Doxorubicin-induced cardiotoxicity. N. Engl. J. Med. 1995 (1995), 1359–1360.
11. [11] King, P.D., Perry, M.C., Hepatotoxicity of chemotherapy. Oncologist 6 (2001), 162–176.
12. [12] Ferry, D.R., Smith, A., Malkhandi, J., Fyfe, D.W., Anderson, D., Baker, J., Kerr, D., Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 2 (1996), 659–668.
13. [13] Moon, Y.J., Wang, L., DiCenzo, R., Morris, M.E., Quercetin pharmacokinetics in humans. Biopharm. Drug Dispos. 29 (2008), 205–217.
14. [14] Dian, L., Cao, X., Xie, Y., Zhu, T., Liang, B., Ou, S., Feng, X., Yu, E., Wen, X., Novel quercetin-loaded mixed micelles with improved dissolution and antioxidant effect. Adv. Sci. Eng. Med. 8 (2016), 233–239.
15. [15] Rodgers, E.H., Grant, M.H., The effect of the flavonoids, quercetin, myricetin and epicatechin on the growth and enzyme activities of MCF7 human breast cancer cells. Chem. Biol. Interact. 116 (1998), 213–228.
16. [16] Paliwal, S., Sundaram, J., Mitragotri, S., Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. Br. J. Cancer 92 (2005), 499–502.
17. [17] Du, G., Lin, H., Wang, M., Zhang, S., Wu, X., Lu, L., Ji, L., Yu, L., Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. Cancer Chemother. Pharmacol. 65 (2010), 277–287.
18. [18] Heeba, G.H., Mahmoud, M.E., Dual effects of quercetin in doxorubicin-induced nephrotoxicity in rats and its modulation of the cytotoxic activity of doxorubicin on human carcinoma cells. Environ. Toxicol., 2014.
19. [19] Choi, J.Y., Ramasamy, T., Tran, H.T., Ku, S.K., Shin, B.S., Choi, H.G., Yong, C.S., Kim, J.O., Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth. J. Mater. Chem. B 3 (2015), 408–416.
20. [20] Choi, J.Y., Thapa, R.K., Yong, C.S., Kim, J.O., Nanoparticle-based combination drug delivery systems for synergistic cancer treatment. J. Pharm. Investigation 46 (2016), 325–339.
21. [21] Ramasamy, T., Tran, T.H., Choi, J.Y., Cho, H.J., Kim, J.H., Yong, C.S., Choi, H.G., Kim, J.O., Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr. Polym. 104 (2014), 653–661.
22. [22] Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007), 751–760.
23. [23] Ramasamy, T., Ruttala, H., Choi, J., Tran, T., Kim, J., Ku, S., Choi, H., Yong, C., Kim, J., Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan. Chem. Commun. 51 (2015), 5758–5761.
24. [24] Ramasamy, T., Choi, J.Y., Cho, H.J., Umadevi, S.K., Shin, B.S., Choi, H.G., Yong, C.S., Polypeptide-based micelles for delivery of irinotecan: physicochemical and in vivo characterization. Pharm. Res. 32:6 (2015), 1947–1956.
25. [25] Park, J.S., Han, T.H., Lee, K.Y., Han, S.S., Hwang, J.J., Moon, D.H., Kim, S.Y., Cho, Y.W., N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. J. Control. Release 115 (2006), 37–45.
26. [26] Ruttala, H.B., Ko, Y.T., Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy. Pharm. Res. 32 (2015), 1002–1016.
27. [27] Liang, X., Liu, F., Kozlovskaya, V., Palchak, Z., Kharlampieva, E., Thermoresponsive micelles from double LCST-poly (3-methyl-N-vinylcaprolactam) block copolymers for cancer therapy. ACS Macro Lett. 4 (2015), 308–311.
28. [28] Kapse-Mistry, S., Govender, T., Srivastava, R., Yergeri, M., Nanodrug delivery in reversing multidrug resistance in cancer cells. Front. Pharmacol., 5, 2014, 159.
29. [29] Varkouhi, A.K., Scholte, M., Storm, G., Haisma, H.J., Endosomal escape pathways for delivery of biologicals. J. Control. Release 151 (2011), 220–228.
30. [30] Sundaramoorthy, P., Ramasamy, T., Mishra, S.K., Jeong, K.Y., Yong, C.S., Kim, J.O., Kim, H.M., Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells. Acta Biomater. 42 (2016), 220–231.
31. [31] Ramasamy, T., Haidar, Z.S., Tran, T.H., Choi, J.Y., Jeong, J.-H., Shin, B.S., Choi, H.-G., Yong, C.S., Kim, J.O., Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs. Acta Biomater. 10 (2014), 5116–5127.
32. [32] Lee, E.S., Shin, H.J., Na, K., Bae, Y.H., Poly (L-histidine)–PEG block copolymer micelles and pH-induced destabilization. J. Control. Release 90 (2003), 363–374.
33. [33] Luo, Z., Jiang, J., PH-sensitive drug loading/releasing in amphiphilic copolymer PAE–PEG: integrating molecular dynamics and dissipative particle dynamics simulations. J. Control. Release 162 (2012), 185–193.
34. [34] Johnson, R.P., Jeong, Y.I., John, J.V., Chung, C.-W., Kang, D.H., Selvaraj, M., Suh, H., Kim, I., Dual stimuli-responsive poly (N-isopropylacrylamide)-b-poly (L-histidine) chimeric materials for the controlled delivery of doxorubicin into liver carcinoma. Biomacromolecules 14 (2013), 1434–1443.
35. [35] Limtrakul, P., Khantamat, O., Pintha, K., Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J. Chemother., 2013.
36. [36] Duraj, J., Zazrivcova, K., Bodo, J., Sulikova, M., Sedlak, J., Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 52 (2004), 273–279.
37. [37] Ramasamy, T., Poudal, B.K., Ruttala, H., Choi, J.Y., Hieu, T.D., Umadevi, K., Youn, Y.S., Choi, H.G., Yong, C.S., Kim, J.O., Cationic drug-based self-assembled polyelectrolyte complex micelles: physicochemical, pharmacokinetic, and anticancer activity analysis. Colloids Surf. B 146 (2016), 152–160.
38. [38] Chou, T.-C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006), 621–681.
39. [39] Green, D.R., Apoptotic pathways: paper wraps stone blunts scissors. Cell 102 (2000), 1–4.
40. [40] Szántó, M., Rutkai, I., Hegedűs, C., Czikora, Á., Rózsahegyi, M., Kiss, B., Virág, L., Gergely, P., Tóth, A., Bai, P., Poly (ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction. Cardiovasc. Res. 92 (2011), 430–438.
41. [41] Walia, V., Kakar, S., Elble, R., Micromanagement of the mitochondrial apoptotic pathway by p53. Front. Biosci. (Landmark Ed.) 16 (2010), 749–758.
42. [42] de David, C., Rodrigues, G., Bona, S., Meurer, L., González-Gallego, J., Tuñón, M.J., Marroni, N.P., Role of quercetin in preventing thioacetamide-induced liver injury in rats. Toxicol. Pathol. 39 (2011), 949–957.
43. [43] Suematsu, N., Hosoda, M., Fujimori, K., Protective effects of quercetin against hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells. Neurosci. Lett. 504 (2011), 223–227.
44. [44] Sassi, N., Biasutto, L., Mattarei, A., Carraro, M., Giorgio, V., Citta, A., Bernardi, P., Garbisa, S., Szabò, I., Paradisi, C., Cytotoxicity of a mitochondriotropic quercetin derivative: Mechanisms. Biochim. Biophys. Acta (BBA) Bioenergetics 2012 (1817), 1095–1106.
45. [45] Gorrini, C., Harris, I.S., Mak, T.W., Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12 (2013), 931–947.
46. [46] Diehn, M., Cho, R.W., Lobo, N.A., Kalisky, T., Dorie, M.J., Kulp, A.N., Qian, D., Lam, J.S., Ailles, L.E., Wong, M., Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458 (2009), 780–783.
47. [47] Liu, F., Kozlovskaya, V., Medipelli, S., Xue, B., Ahmad, F., Saeed, M., Cropek, D., Kharlampieva, E., Temperature-sensitive polymersomes for controlled delivery of anticancer drugs. Chem. Mater. 27 (2015), 7945–7956.
48. [48] Xue, B., Kozlovskaya, V., Liu, F., Chen, J., Williams, J.F., Campos-Gomez, J., Saeed, M., Kharlampieva, E., Intracellular degradable hydrogel cubes and spheres for anti-cancer drug delivery. ACS Appl. Mater. Interfaces 7 (2015), 13633–13644.
49. [49] Fang, E.F., Zhang, C.Z.Y., Zhang, L., Wong, J.H., Chan, Y.S., Pan, W.L., Dan, X.L., Yin, C.M., Cho, C.H., Ng, T.B., Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis. PLoS One, 7, 2012, e41592.
50. [50] Qin, Y., Sun, C.-Y., Lu, F.-R., Shu, X.-R., Yang, D., Chen, L., She, X.-M., Gregg, N.M., Guo, T., Hu, Y., Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro. Leuk. Res. 36 (2012), 514–520.
51. [51] DeLisser, H., Liu, Y., Desprez, P.-Y., Thor, A., Briasouli, P., Handumrongkul, C., Wilfong, J., Yount, G., Nosrati, M., Fong, S., Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression. Proc. Natl. Acad. Sci. 107 (2010), 18616–18621.
52. [52] Awasthi, N., Zhang, C., Ruan, W., Schwarz, M.A., Schwarz, R.E., BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol. Cancer Ther. 11 (2012), 2644–2653.